You are here: Industry Insights > Bevacizumab

News List

Qilu Pharmaceutical Achieved Staggering Sales of Bevacizumab of RMB1.8 Billion in 2020 PharmaSources/Caicai
March 04, 2021
According to industry news, Qilu Pharmaceutical achieved sales of bevacizumab (trade name: Ankeda) of about RMB1.8 billion in 2020.
Innovent and Eli Lilly announce final clinical results and biomarker analysis of phase-Ib study of Sintilimab injection plus Bevacizumab biosimilar injection ExpressPharma
January 24, 2022
The Overall Response Rate (ORR) was 34 per cent (17/50) and ORRs for the low-dose and high-dose groups were 31 per cent and 38 per cent, respectively...
Henlius' 4th Biologics: Bevacizumab Biosimilar Hanbeitai Approved by National Medical Products Administration prnasia
December 06, 2021
Shanghai Henlius Biotech, Inc. (2696.HK) announced that bevacizumab biosimilar Hanbeitai, developed and manufactured by Henlius independently, has been approved by the National Medical Products Administration (NMPA).
NaviFUS begins clinical trial for brain tumour treatment europeanpharmaceuticalreview
August 06, 2021
NaviFUS® was approved by the Taiwan, China FDA for use in a new clinical trial for the treatment of terminal primary brain tumours.
China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma prnasia
July 22, 2021
Ascletis Pharma Inc. today announces that China National Medical Products Administration (NMPA) has approved the Phase III clinical trial application of ASC40 combined with Bevacizumab for treatment of patients with recurrent glioblastoma.
Merck’s KEYTRUDA Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Cervical Cancer americanpharmaceuticalreview
June 23, 2021
Merck announced that the pivotal Phase 3 KEYNOTE-826 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (paclitaxel plus cisplatin or paclitaxel plus carboplatin) with or without bevacizumab ...
US FDA accepts Amneal’s Biologics License Application for Bevacizumab expresspharma
June 18, 2021
Bevacizumab represents the third biosimilar BLA currently filed by Amneal with the FDA.
Biocon Biologics, Viatris get EC approval for biosimilar Bevacizumab expresspharma
April 27, 2021
Abevmy 100 and 400 mg is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.
Ascletis Announces Investment Escalation in R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors prnasia
March 30, 2021
Ascletis Pharma Inc. announces today that the board of directors of the Company has resolved to deploy more resources and investment in the R&D of cancer lipid metabolism and oral checkpoint inhibitors.
Anticancer drug may improve outcome for severe COVID-19 patients worldpharmanews
February 10, 2021
Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China that was led by researchers at Karolinska Institutet in Sweden between February ...

Previous page 1 2 3 Next page